COMPARATIVE PERFORMANCE OF HUMAN PAPILLOMAVIRUS MESSENGER RNA VERSUS DNA screening TESTS at baseline and 48 months IN THE HPV FOCAL Trial

Screening programs are beginning to replace Pap cytology with high-risk (hr) HPV for primary cervical cancer screening (1 –3). Multiple randomized trials utilizing the Hybrid Capture 2 High-Risk HPV DNA Test (HC2) (4–7), GP5/GP6 PCR-based hrHPV assays (8) and the cobas 4800 HPV test (9) have demonstrated earlier detection of high-grade cervical lesions (cervical intraepithelial neoplasia [CIN] grade 2 or worse [CIN 2+]) compared to cytology, which reflects the safety of extending the re-screening interval following negative primary hrHPV DNA screening.

Source: Journal of Clinical Virology - September 10, 2018 Category: Virology Authors: Darrel A. Cook, Laurie W. Smith, Jennifer H. Law, Wendy Mei, Lovedeep Gondara, Dirk J. van Niekerk, Kathy M. Ceballos, Dan Jang, Max Chernesky, Eduardo L. Franco, Gina S. Ogilvie, Andrew J. Coldman, Mel Krajden Source Type: research